Clinical Trial Update: SMOFlipid to Lessen the Severity of Neonatal Cholestasis [Phase 1, Phase 2]

View source ↗

Summary

A University of Florida trial evaluating SMOFlipid to lessen the severity of neonatal cholestasis in Phase 1/2 has been terminated, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholestasis
• Neonatal Cholestasis
• Obstructive Jaundice

Drugs mentioned

• SMOFLIPID

Snippet

Sponsor: University of Florida | Conditions: Cholestasis, Jaundice, Obstructive | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2017-04-17